In order to validate whether these del(11q)/ATM-mutated CRISPR/Cas9 models could be used as a predictive preclinical tool for the study of novel therapeutic approaches, we examined the effects of the combination of olaparib and ibrutinib ex vivo in primary cells from a cohort of 38 CLL samples (non-del(11q) n = 23; del(11q) n = 15). This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.